ReviewHealthcare (Basel, Switzerland)2023
Pharmacological Support for the Treatment of Obesity-Present and Future.
Review in Healthcare (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis.International journal of obesity (2005) · 2025 · on this mapPooled it
- Pooled it
- Advances in GLP-1 receptor agonists delivery systems for obesity and diabetes.Acta pharmaceutica Sinica. B · 2026Review
- Anti-Adipogenic Effects of Probiotic Lactiplantibacillus pentosus THF59 via Inhibition of Differentiation and Promotion of Apoptosis in 3T3-L1 Cells.Probiotics and antimicrobial proteins · 2026Article
- Sugar tax in Poland: population-level trends in obesity, sugar consumption and healthcare utilization.Frontiers in public health · 2026Article
- The Gut Microbiome in Human Obesity: A Comprehensive Review.Biomedicines · 2025Review
- Ghrelin and LEAP2: Their Interaction Effect on Appetite Regulation and the Alterations in Their Levels Following Bariatric Surgery.Medicina (Kaunas, Lithuania) · 2025Review
- Article
- Perspectives in clinical research on acupuncture treatment for central obesity: A perspective.Medicine · 2025Review
- An integrated view of the pathophysiological crosstalk between adipose tissue, bone and cardiovascular system in men and women.Journal of endocrinological investigation · 2025Review
- Effects of Pregnancy and Lactation on Bone Microstructure and Material Properties in a Rat Model of Bariatric Surgery.Calcified tissue international · 2025Article
- Weight cycling exacerbates glucose intolerance and hepatic triglyceride storage in mice with a history of chronic high fat diet exposure.Journal of translational medicine · 2025Article
- Efficacy of Simplifying Complex Insulin Regimen on Glycometabolic Parameters and Target Organ Damage in Type 2 Diabetes: A Retrospective Cohort Study.Journal of diabetes research · 2025Article
- Mobilizing Stockpile of Nature: Phytochemicals, Herbal Extracts, and Dietary Supplements for Managing Metabolic Diseases with Concentric Focus on Obesity.Endocrine, metabolic & immune disorders drug targets · 2025Review
- Electroacupuncture improves lipid metabolism via proteome and gut microbiota profiling in obese rats.American journal of translational research · 2025Article
- Transformative weight loss with Dulaglutide: A case report of success in a challenging patient profile of an ex-sumo wrestler.Clinical case reports · 2024Article
- A Systematic Review of Cardio-Metabolic Properties ofAntioxidants (Basel, Switzerland) · 2024Review
- Anti-Obesity Effects of Chitosan and Its Derivatives.Polymers · 2023Review
- Family Medicine and Primary Healthcare: The Past, Present and Future.Healthcare (Basel, Switzerland) · 2023Article
- 360-Degree Perspectives on Obesity.Medicina (Kaunas, Lithuania) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a growing civilization problem, associated with a number of negative health consequences affecting almost all tissues and organs. Currently, obesity treatment includes lifestyle modifications (including diet and exercise), pharmacologic therapies, and in some clinical situations, bariatric surgery. These treatments seem to be the most effective method supporting the treatment of obesity. However, they are many limitations to the options, both for the practitioners and patients. Often the comorbidities, cost, age of the patient, and even geographic locations may influence the choices. The pharmacotherapy of obesity is a fast-growing market. Currently, we have at our disposal drugs with various mechanisms of action (directly reducing the absorption of calories-orlistat, acting centrally-bupropion with naltrexone, phentermine with topiramate, or multidirectional-liraglutide, dulaglutide, semaglutide). The drugs whose weight-reducing effect is used in the course of the pharmacotherapy of other diseases (e.g., glucose-sodium cotransporter inhibitors, exenatide) are also worth mentioning. The obesity pharmacotherapy is focusing on novel therapeutic agents with improved safety and efficacy profiles. These trends also include an assessment of the usefulness of the weight-reducing properties of the drugs previously used for other diseases. The presented paper is an overview of the studies related to both drugs currently used in the pharmacotherapy of obesity and those undergoing clinical trials, taking into account the individual approach to the patient.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.